Literature DB >> 29020420

Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency.

Rehan M Hussain, Seenu M Hariprasad, Thomas A Ciulla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29020420     DOI： 10.3928/23258160-20170928-01

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN： 2325-8160            Impact factor:   1.300


× No keyword cloud information.
  7 in total

Review 1.  Challenges and opportunities for drug delivery to the posterior of the eye.

Authors:  Fernando J Cabrera; Daniel C Wang; Kartik Reddy; Ghanashyam Acharya; Crystal S Shin
Journal:  Drug Discov Today       Date:  2019-06-05       Impact factor: 7.851

2.  Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.

Authors:  Ruslan Grishanin; Brian Vuillemenot; Pallavi Sharma; Annahita Keravala; Judith Greengard; Claire Gelfman; Mark Blumenkrantz; Matthew Lawrence; Wenzheng Hu; Szilárd Kiss; Mehdi Gasmi
Journal:  Mol Ther       Date:  2018-11-13       Impact factor: 11.454

3.  Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration.

Authors:  Justus G Garweg
Journal:  Clin Ophthalmol       Date:  2019-07-19

Review 4.  Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.

Authors:  Saira Khanna; Rahul Komati; David A Eichenbaum; Ishani Hariprasad; Thomas A Ciulla; Seenu M Hariprasad
Journal:  BMJ Open Ophthalmol       Date:  2019-12-15

5.  Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.

Authors:  Claire M Gelfman; Ruslan Grishanin; Kristina Oresic Bender; Aivan Nguyen; Judith Greengard; Pallavi Sharma; Julio Nieves; Szilárd Kiss; Mehdi Gasmi
Journal:  J Ocul Pharmacol Ther       Date:  2021-04       Impact factor: 2.671

Review 6.  Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions.

Authors:  Thales Antonio Cabral de Guimaraes; Michalis Georgiou; James W B Bainbridge; Michel Michaelides
Journal:  Br J Ophthalmol       Date:  2020-04-08       Impact factor: 4.638

Review 7.  Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.

Authors:  Rehan M Hussain; Bilal A Shaukat; Lauren M Ciulla; Audina M Berrocal; Jayanth Sridhar
Journal:  Drug Des Devel Ther       Date:  2021-06-21       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.